Expert evaluation suggests targeted therapies improve efficacy and safety in immunotherapy for ITP, highlighting future research on biomarkers.
Therapeutic options for ITP are rapidly expanding beyond conventional immunosuppressants and splenectomy. Emerging targeted therapies offer the promise of improved efficacy, better safety profiles, and the potential for durable, treatment-free remission. Future research should focus on personalized medicine approaches, biomarker identification for predicting treatment response, optimizing treatment sequencing, and understanding long-term outcomes to transform ITP care.
No takes yet. Share an insight, caveat, or question.
Charbel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: